Research ArticleClinical Studies
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers
EIJI KONDO, RYO NIMURA, SHINTARO MAKI, MICHIKO KANEDA, MASAFUMI NII, KENTA YOSHIDA, TSUTOMU TABATA and TOMOAKI IKEDA
Anticancer Research August 2021, 41 (8) 4157-4161; DOI: https://doi.org/10.21873/anticanres.15219
EIJI KONDO
1Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
RYO NIMURA
1Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
SHINTARO MAKI
1Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
MICHIKO KANEDA
1Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
MASAFUMI NII
1Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
KENTA YOSHIDA
1Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
TSUTOMU TABATA
2Department of Obstetrics and Gynecology, Tokyo Women’s Medical University, Tokyo, Japan
TOMOAKI IKEDA
1Department of Obstetrics and Gynecology, Mie University School of Medicine, Mie, Japan
In this issue
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers
EIJI KONDO, RYO NIMURA, SHINTARO MAKI, MICHIKO KANEDA, MASAFUMI NII, KENTA YOSHIDA, TSUTOMU TABATA, TOMOAKI IKEDA
Anticancer Research Aug 2021, 41 (8) 4157-4161; DOI: 10.21873/anticanres.15219
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers
EIJI KONDO, RYO NIMURA, SHINTARO MAKI, MICHIKO KANEDA, MASAFUMI NII, KENTA YOSHIDA, TSUTOMU TABATA, TOMOAKI IKEDA
Anticancer Research Aug 2021, 41 (8) 4157-4161; DOI: 10.21873/anticanres.15219
Jump to section
Related Articles
- No related articles found.